Evidence map›Paper›PMID 42396448›Full record

Observational studyFrontiers in immunology2026

Outcomes of belatacept-based quadruple immunosuppression therapy in kidney transplant recipients with persistent alloimmune response: a single-center observational study.

Basheer Ahamad Kummangal, Ali Olyaei, Angelo de Mattos, Shehzad Rehman, Justin Smith, Megan Stack, Zoha Ahmad, Jay Pandav

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Basheer Ahamad KummangalDivision of Nephrology and Hypertension, Oregon Health and Science University, Portland, OR, United States.
Ali OlyaeiDivision of Nephrology and Hypertension, Oregon Health and Science University, Portland, OR, United States.
Angelo de MattosDivision of Nephrology and Hypertension, Oregon Health and Science University, Portland, OR, United States.
Shehzad RehmanDivision of Nephrology and Hypertension, Oregon Health and Science University, Portland, OR, United States.
Justin SmithDivision of Nephrology and Hypertension, Oregon Health and Science University, Portland, OR, United States.
Megan StackDivision of Nephrology and Hypertension, Oregon Health and Science University, Portland, OR, United States.
Zoha AhmadDivision of Nephrology and Hypertension, Oregon Health and Science University, Portland, OR, United States.
Jay PandavDivision of Nephrology and Hypertension, Oregon Health and Science University, Portland, OR, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We conducted a retrospective review of adult kidney transplant recipients (KTRs) who received belatacept in addition to calcineurin inhibitors, antimetabolites, and corticosteroids for recurrent or refractory rejection or for persistent donor-specific antibodies (DSAs) unresponsive to standard therapy. Fifteen recipients were included. Kidney function remained stable on follow-up; median eGFR was 52 mL/min (R 23-91) at baseline and 54 mL/min (R 25-105) at 6 months (

Indexed as

AbataceptGraft RejectionImmunosuppressive AgentsKidney TransplantationAdultAgedDrug Therapy, CombinationFemaleGraft SurvivalHumansImmunosuppression TherapyIsoantibodiesMaleMiddle AgedRetrospective StudiesTreatment OutcomeAbataceptImmunosuppressive AgentsIsoantibodiesbelataceptdonor specific antibodiesimmunosuppressionkidney transplantationrejection

Identifiers

PMID42396448
PMCPMC13322944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.